According to IMARC’s latest report“Global Biopharmaceutical Manufacturing Market Report 2016-2021”, the global biopharmaceutical manufacturing capacity has grown at a CAGR of more than 6% during 2008-2015. This market is currently being driven by improved technologies and processes, emergence of biosimilars, entry of new players, growing demand for vaccines & biologic drugs worldwide and an increase in the global ageing population. To know more visit website: http://www.imarcgroup.com/global-biopharmaceutical-manufacturing-market

1. Imarc
www.imarcgroup.com
Consulting Services
Copyright © 2016 International Market Analysis Research & Consulting (IMARC). All Rights Reserved
Global Biopharmaceutical
Manufacturing Market
Witnessing a Shift Towards
Contract Manufacturing
Organisations

2. The International Market Analysis Research and Consulting Group is a leading advisor on management
strategy and market research worldwide. We partner with clients in all sectors and regions to identify
their highest-value opportunities, address their most critical challenges, and transform their
businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food
and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the
company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.
Report DescriptionAbout IMARC Group
Imarc
www.imarcgroup.com

3. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
Global Biopharmaceutical Manufacturing Market Witnessing a Shift Towards Contract
Manufacturing Organisations
Biopharmaceutical manufacturing is a cost-intensive and time taking process which requires
expertise. In order to reduce manufacturing costs, biopharmaceutical companies are outsourcing
their manufacturing operations to Contract Manufacturing Organisations (CMOs).
According to IMARC’s study “Global Biopharmaceutical Manufacturing Market Report 2016-2021”,
the global biopharmaceutical manufacturing capacity has grown at a CAGR of more than 6% during
2008-2015. Compared to pharmaceutical products which are synthesized chemically,
biopharmaceuticals are manufactured from biological sources. However, their development and
production is a complex and delicate process involving superior technology and highly skilled work
force. The production facilities are also more expensive and require more time to set-up as
compared to small molecule drugs. These facilities are also significantly costlier to run and involve
long process durations, low yields and expensive raw materials. The global biopharmaceutical
manufacturing market is currently being driven by improved technologies and processes, emergence
of biosimilars, entry of new players, growing demand for vaccines & biologic drugs worldwide and an
increase in the global ageing population.

4. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
Browse press release: http://www.imarcgroup.com/global-biopharmaceutical-manufacturing-
market-report
Currently, biopharmaceuticals represent the fastest developing segment of the global pharmaceutical
market. The increasing popularity of biopharmaceuticals and high returns have led to a number of
companies developing and manufacturing them. In most cases biopharmaceuticals are manufactured
in-house by innovator companies. This trend, however, is changing and shifting towards contract
manufacturing organizations (CMOs). This trend is currently being driven both by significant cost
savings and the recognition that contract manufacturing organizations (CMOs) can be more effective,
innovative and efficient partners with specific capabilities that can even exceed those available in-
house.
IMARC’s report provides a detailed analysis of the biopharmaceutical manufacturing market. The report
has segmented the market on the basis of the cell culture used for manufacturing biopharmaceuticals.
Findings from the report suggest that mammalian cell culture currently dominates the global
biopharmaceutical production. The report has also studied the biopharmaceuticals manufacturing
market on the basis of class. The classes covered in the report include – monoclonal antibodies,
recombinant proteins, interferons, granulocyte colony-stimulating factor (G-CSF),erythropoietin,
recombinant human insulin, vaccines and human growth hormones (HGH).

5. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
On the basis of geographical segmentation, the report has covered Asia, Europe and North America.
Currently, North America dominates the global biopharmaceuticals manufacturing market accounting
for nearly half of the total market share followed by Europe and Asia. Asia, on the other hand,
represents the fastest growing market for biopharmaceutical manufacturing. The report has also
analysed the competitive landscape of the global biopharmaceutical manufacturing market. Some of
the key players covered by the report include – Roche Ltd., Amgen, Novo Nordisk, AbbVie, Sanofi S.A,
Johnson & Johnson, Pfizer, Merck & Co., Eli Lilly and Company, and Biogen Idec, Inc.
Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form/

6. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
Table of Contents
1 Research Methodology and Market Definitions
2 Executive Summary
3 Global Biopharmaceutical Market: Key Trends
3.1 Biopharmaceuticals are Growing Faster than Small Molecule Drugs
3.2 Growth of Biosimilars will Push Volumes and Introduce New Players in this Market
3.3 A Rich Biopharmaceutical Pipeline will Drive the Capacity Demand in the Coming Years
3.4 Increasing Trends in Mergers and Acquisitions will Increase Redundant Capacities
3.5 Increasing Focus on Personalized Medicines and High Value Low Volume Markets
3.6 Higher Titers will Reduce Capacity Demand
3.7 Growth in the Use of Cost Effective Disposable Technologies
3.8 Despite Sufficient Global Capacity, Its Uneven Distribution will Continue to Spur Demand
4 Global Biopharmaceutical Market: Industry Performance
4.1 Current and Historical Sales Trends
4.2 Market Breakup by Region
4.3 Market Breakup by Expression Systems
4.4 Market Breakup by Product Type
4.5 Market Outlook
5 Regional Biopharmaceutical Market Analysis
5.1 United States

7. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
5.1.1 Current and Historical Sales Trends
5.1.2 Market Outlook
5.2 Canada
5.2.1 Current and Historical Sales Trends
5.2.2 Market Outlook
5.3 United Kingdom
5.3.1 Current and Historical Sales Trends
5.3.2 Market Outlook
5.4 Germany
5.4.1 Current and Historical Sales Trends
5.4.2 Market Outlook
5.5 France
5.5.1 Current and Historical Sales Trends
5.5.2 Market Outlook
5.6 Italy
5.6.1 Current and Historical Sales Trends
5.6.2 Market Outlook
5.7 Spain
5.7.1 Current and Historical Sales Trends
5.7.2 Market Outlook
5.8 Russia

8. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
5.8.1 Current and Historical Sales Trends
5.8.2 Market Outlook
5.9 Brazil
5.9.1 Current and Historical Sales Trends
5.9.2 Market Outlook
5.10 Australia
5.10.1 Current and Historical Sales Trends
5.10.2 Market Outlook
6 Global Biopharmaceutical Manufacturing Industry
6.1 Current and Historical Manufacturing Capacity Trends
6.2 Market Breakup by Region
6.2.1 North America
6.2.1.1 Current and Historical Manufacturing Capacity Trends
6.2.1.2 Market Outlook
6.2.2 Europe
6.2.2.1 Current and Historical Manufacturing Capacity Trends
6.2.2.2 Market Outlook
6.2.3 Asia
6.2.3.1 Current and Historical Manufacturing Capacity Trends
6.2.3.2 Market Outlook
6.3 Market Breakup by Cell Culture

9. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
6.3.1 Mammalian Cell Culture
6.3.1.1 Key Market Drivers
6.3.1.2 Current and Historical Sales Trends
6.3.1.3 Current and Historical Manufacturing Capacity Trends
6.3.1.4 Market Breakup by Region
6.3.1.5 Market Breakup by Product Type
6.3.1.6 Key Players
6.3.1.7 Market Outlook
6.3.2 Microbial Cell Culture
6.3.2.1 Key Market Drivers
6.3.2.2 Current and Historical Sales Trends
6.3.2.3 Current and Historical Manufacturing Capacity Trends
6.3.2.4 Market Breakup by Product
6.3.2.5 Market Breakup by Region
6.3.2.6 Key Players
6.3.2.7 Market Outlook
6.4 Market Breakup by Class
6.4.1 Monoclonal Antibodies
6.4.1.1 Current and Historical Sales Trends
6.4.1.2 Market Outlook
6.4.2 Recombinant Proteins

10. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
6.4.2.1 Current and Historical Sales Trends
6.4.2.2 Market Outlook
6.4.3 Interferon
6.4.3.1 Current and Historical Sales Trends
6.4.3.2 Market Outlook
6.4.4 Granulocyte Colony-Stimulating Factor (G-CSF)
6.4.4.1 Current and Historical Sales Trends
6.4.4.2 Market Outlook
6.4.5 Erythropoietin
6.4.5.1 Current and Historical Sales Trends
6.4.5.2 Market Outlook
6.4.6 Recombinant Human Insulin
6.4.6.1 Current and Historical Sales Trends
6.4.6.2 Market Outlook
6.4.7 Vaccines
6.4.7.1 Current and Historical Sales Trends
6.4.7.2 Market Outlook
6.4.8 Human Growth Hormones (HGH)
6.4.8.1 Current and Historical Sales Trends
6.4.8.2 Market Outlook
6.5 Market Outlook

11. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
7 Competitive Landscape
7.1 Market Breakup by Manufacturer Type
7.1.1 Product Companies
7.1.2 Contract Manufacturers
7.2 Key Player Profiles
7.2.1 Roche
7.2.1.1 Company Overview
7.2.1.2 Key Financials
7.2.2 Amgen
7.2.2.1 Company Overview
7.2.2.2 Key Financials
7.2.3 Novo Nordisk
7.2.3.1 Company Overview
7.2.3.2 Key Financials
7.2.4 AbbVie
7.2.4.1 Company Overview
7.2.4.2 Key Financials
7.2.5 Sanofi S.A
7.2.5.1 Company Overview
7.2.5.2 Key Financials
7.2.6 Johnson & Johnson

12. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
7.2.6.1 Company Overview
7.2.6.2 Key Financials
7.2.7 Pfizer
7.2.7.1 Company Overview
7.2.7.2 Key Financials
7.2.8 Merck & Co.
7.2.8.1 Company Overview
7.2.8.2 Key Financials
7.2.9 Lilly
7.2.9.1 Company Overview
7.2.9.2 Key Financials
7.2.10 Biogen Idec
7.2.10.1 Company Overview
7.2.10.2 Key Financials

13. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia:
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group North America:
Email: america@imarcgroup.com
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa:
Email: ema@imarcgroup.com
Phone: +44-702-409-7331
To know more please visit: http://www.imarcgroup.com/global-biopharmaceutical-manufacturing-market

14. Report DescriptionReport Description and Highlights
Imarc
www.imarcgroup.com
© 2016 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

15. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +91-120-4155099
E-MAIL: sales@imarcgroup.com
http://www.imarcgroup.com
Contact Us